We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dupixent was previously shot down in April by the UK’s National Institute for Health Care and Excellence over concerns about the drug’s cost-effectiveness. Read More
The agency’s green light for Lorbrena marks Pfizer’s third approval for an oncology treatment — including two lung cancer treatments — within two months. Read More